Investing Insights: Is Pfizer (PFE) a Compelling Value Play?
Former pharmaceutical champion Pfizer (PFE) has seen better days, with the stock down 52% from its December 2021 all-time high. However, some experts believe that Pfizer is showing signs of a “bearish-to-bullish” reversal, making it an interesting opportunity for investors.
Pfizer, once the most valuable large-cap pharma stock in the world, has faced challenges over the past few years. At its current price of $29.30 per share, the stock is trading only slightly above its March 2020 Covid low of $26.32. Despite this, Pfizer has recently been exhibiting bullish price-volume correlation and good relative strength compared to its peers in the S & P 500 Pharmaceuticals Industry Group.
According to investment analyst Carter Braxton Worth, PFE represents a compelling “value play” at its current levels. With a dividend yield of 5.73%, investors can also benefit from getting paid while waiting for the stock to potentially bottom out.
For those looking for actionable recommendations and insights, becoming a member at worthcharting.com could provide valuable information via email and live nightly videos. It’s important to note that all opinions expressed in this article are solely those of the author and do not necessarily reflect the opinions of CNBC, NBC UNIVERSAL, or their affiliates.
Keep in mind that the above information is for informational purposes only and should not be taken as financial, investment, tax, or legal advice. Before making any financial decisions, it’s recommended to seek advice from a financial or investment advisor based on your individual circumstances.
For more investing tips and insights, visit Extreme Investor Network for valuable content tailored to help you make informed investment decisions. Don’t miss out on exclusive articles, expert analysis, and actionable recommendations that can help you navigate the complex world of investing with confidence.